Erin S. Enright - 14 Jan 2022 Form 4 Insider Report for Brooklyn ImmunoTherapeutics, Inc. (ERNA)

Reporting relationship: Director
Issuer ticker: ERNA
Reported as of: 14 Jan 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 Jan 2022, 20:46:16 UTC
Prior SEC filing: 05 Jan 2022
Next SEC filing: 05 Apr 2022
Source filing: View source filing
Reporting owner signature: /s/ Erin. S. Enright

Key filing fact

Erin S. Enright filed Form 4 for Brooklyn ImmunoTherapeutics, Inc. (ERNA) on 19 Jan 2022.

Key facts

This page summarizes Erin S. Enright's Form 4 filing for Brooklyn ImmunoTherapeutics, Inc. (ERNA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 19 Jan 2022, 20:46.

Change

Previous filing in this sequence was filed on 05 Jan 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ERNA transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +67,000
Change %
Price: $0.000000
Shares after: 67,000
Date: 14 Jan 2022
Ownership: Direct
Underlying class: Common Stock, par value $0.005 per share
Underlying amount: 67,000
Exercise price: $3.22
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock option vests (subject to continued service) with respect to 22,336 shares of common stock on the first anniversary of the grant date and then in subsequent monthly installments of 1,861 shares of common stock through the three-year anniversary of the grant date.